Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes

The COVID-19 pandemic-related constraints on healthcare access have raised concerns about adverse outcomes from delayed treatment, including the risk of cancer progression and other complications. Further, concerns were raised about a potentially significant backlog of patients in need of cancer care due to the pandemic-related delays in healthcare, further exacerbating any potential adverse outcomes. Delayed access to surgery is particularly relevant to urologic oncology since one-third of new cancers in men (20% overall) arise from the genitourinary (GU) tract and surgery is often the primary treatment. Herein, we summarize the prepandemic literature on deferred surgery for GU cancers and risk of disease progression. The aforementioned data on delayed surgery were gathered in the context of systemic delays present in certain healthcare systems, or occasionally, due to planned deferral in suboptimal surgical candidates. These data provide indirect, but sufficient insight to develop triage schemas for prioritization of uro-oncological cases. Herein, we outline the extent to which the pandemic-related triage guidelines had influenced urologic practice in various regions. To study the adverse outcomes in the pandemic-era, a survey of urologic oncologists was conducted regarding modifications in their initial management of urologic cancers and any delay-related adverse outcomes. While the adverse effects directly from COVID-19 related delays will become apparent in the coming years, the results showing short-term outcomes are quite instructive. Since cancer care was assigned a higher priority at most centers, this strategy may have avoided significant delays in care and limited the anticipated negative impact of pandemic-related constraints. (C) 2020 Elsevier Inc. All rights reserved.

Automated summary

The constraints on healthcare access during the COVID-19 pandemic have raised concerns about adverse outcomes from delayed treatment, especially in cancer care. Studies on deferred surgery for urologic cancers and risk of disease progression provide insight for prioritization of cases, while pandemic-related triage guidelines have influenced urologic practice in various regions. Conducting surveys among urologic oncologists to study modifications in initial management and delay-related adverse outcomes can help in understanding the short-term impact of COVID-19 delays on cancer care.